Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not ...

CHATHAM, NJ / ACCESS Newswire / March 31, 2025 /This post was written and published as a collaboration between the in-house ...

Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has surged by 10.44%, which has investors questioning if this is right ...

FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price ...

Tonix Pharmaceuticals (TNXP) stock falls as the company misses Street forecasts on Q4 2024 revenue miss ahead of an FDA ...

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Tonix Pharma (TNXP – Research Report), with a price ...

CHATHAM, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and ...

A copy of the Company’s poster will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be ...

Analysts say these cheap stocks have plenty of upside.